Skip to main content
PTC THERAPEUTICS, INC. logo

PTC THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PTCT ISIN · US69366J2006 LEI · 549300UJLWOIWFDGB318 US Manufacturing
Open in API
Filings indexed 1,161 across all filing types
Latest filing 2021-01-07 Capital/Financing Update
Country US United States of America
Listing US PTCT

About PTC THERAPEUTICS, INC.

https://www.ptcbio.com/

PTC Therapeutics, Inc. is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated medicines for children and adults with rare and serious diseases. The company focuses on conditions with high unmet medical needs, leveraging its expertise across multiple scientific platforms. These platforms include RNA biology, with a focus on splicing modification to control protein production, and targeting inflammation and ferroptosis pathways for central nervous system diseases. PTC has brought several pioneering treatments to market, including the first approved therapy for Duchenne muscular dystrophy, the first gene therapy administered directly into the brain, and the first small molecule splicing modifier. The company maintains a diversified pipeline of innovative therapies.

Recent filings

Filing Released Lang Actions
POSASR
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to a Form S-3 Registration Statement filed with the SEC by PTC Therapeutics, Inc. It pertains to deregistration of unsold securities and termination of the effectiveness of the registration statement. The document is a regulatory filing related to securities registration and deregistration, not a financial report, earnings release, or management discussion. It is a formal SEC filing about capital structure and registration status, which fits the Capital/Financing Update (CAP) category as it deals with securities registration and deregistration. The document length is 6982 characters, sufficient to be a substantive filing rather than a brief announcement. Therefore, the best classification is CAP with high confidence.
2021-01-07 English
FORM POSASR
Regulatory Filings Classification · 100% confidence The document is a Post-Effective Amendment No. 1 to a Form S-3 Registration Statement filed with the SEC. It pertains to deregistration of unsold securities and termination of the effectiveness of the registration statement. The document is a regulatory filing related to securities registration and deregistration, not a financial report, earnings release, or management discussion. It is a formal SEC filing updating the status of a registration statement, which fits the category of Regulatory Filings (RNS). The document length is 7014 characters, which is sufficient for a substantive filing but it is clearly an amendment to a registration statement, not a report or announcement of a report publication. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-01-07 English
FORM 4 -
Director's Dealing
2021-01-06 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by PTC Therapeutics, Inc. Form S-8 is used for registering securities to be offered under employee benefit plans, such as stock incentive plans. The text includes details about the securities to be registered, the plans involved, indemnification provisions, and exhibits related to the registration. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2021-01-04 English
FORM 4 -
Director's Dealing
2020-12-31 English
FORM 4 -
Director's Dealing
2020-12-16 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.